Vitamin D supplementation, lung function, and asthma control in children with asthma and low vitamin D levels.

Vitamin D supplementation, compared with placebo, had no significant effect on percent predicted lung function measures (FEV1, FVC, or FEV1/FVC), asthma control, or asthma-related quality of life in children with asthma and low vitamin D levels. Observational studies have shown that low vitamin D levels are linked to worse lung function and poor asthma control in children with asthma. We hypothesized that vitamin D supplementation would improve function, disease control, and quality of life in children with asthma (ages 6–16 years) and vitamin D levels below 30 ng·mL−1. We tested this hypothesis in a secondary analysis of data from the Vitamin D Kids Asthma Study (VDKA), a randomized, double-blind, parallel, placebo-controlled clinical trial. Each participant in the VDKA was randomly assigned to either daily placebo capsules or daily vitamin D3 (4000 IU) plus low-dose inhaled fluticasone propionate. Of the 192 randomized participants, 176 were included in the analysis of change in percent predicted lung function measures (FEV1, FVC, and FEV1/FVC) and asthma control scores. Of these 176 participants, 94 were also included in the analysis of change in asthma-related quality of life scores, as they were 10 years and older. Linear regression was used for the multivariable analysis of vitamin D supplementation and each outcome, which was adjusted for study site, race, sex, and time in the study. In this analysis, vitamin D supplementation was not significantly associated with change in any outcome (lung function measures, asthma control, or asthma-related quality of life) between the randomization and exit visits. Our results do not support recommending vitamin D supplementation to improve lung function, asthma control, or asthma-related quality of life in children with asthma and vitamin D levels below 30 ng·mL−1. Footnotes This manuscript has recently been accepted for publication in the European Respiratory Journal . It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article. Conflict of interest: Dr. Han has nothing to disclose. Conflict of interest: Dr. Forno has nothing to disclose. Conflict of interest: Dr. Bacharier has nothing to disclose. Conflict of interest: Dr. Phipatanakul reports personal fees from GSK, Genentech, Novartis, Regeneron, Sanofi, and Teva, grants from Genentech, Novartis, Regeneron, Sanofia, Circassia, Monaghen, Thermo Fisher, Alk Abello, Lincoln Diagnostics, GSK, Kaleo, and Merck, grants from Genentech, Regeneron, Novartis, and the US NIH, outside the submitted work; . Conflict of interest: Dr. Guilbert reports personal fees from American Board of Pediatrics (Pediatric Pulmonary Sub-board), GSK, TEVA, and Sanofi/Regeneron, grants from Astra-Zeneca, Novartis, and Sanofi/Regeneron, non-financial support from Up To Date, outside the submitted work; . Conflict of interest: Dr. Cabana reports other from United States Preventive Services Task Force (USPSTF), outside the submitted work; . Conflict of interest: Dr. Ross has nothing to disclose. Conflict of interest: Dr. Blatter has nothing to disclose. Conflict of interest: Dr. Rosser has nothing to disclose. Conflict of interest: Dr. Durrani has nothing to disclose. Conflict of interest: Dr. Luther has nothing to disclose. Conflict of interest: Dr. Wisniewski has nothing to disclose. Conflict of interest: Dr. Celedon reports non-financial support from Pharmavite and GSK, during the conduct of the study; non-financial support from Merck, outside the submitted work.Dr. Celedon reports non-financial support from Pharmavite and GSK, during the conduct of the study; non-financial support from Merck, outside the submitted work; .